$ENTA
ENANTA PHARMACEUTICALS INC

2018 Q2 Form 10-Q Financial Statement

#000156459018021062 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $57.26M $7.511M
YoY Change 662.38% -46.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.140M $5.230M
YoY Change 17.4% 22.2%
% of Gross Profit
Research & Development $28.49M $15.41M
YoY Change 84.86% 42.88%
% of Gross Profit
Depreciation & Amortization $660.0K $550.0K
YoY Change 20.0% 25.0%
% of Gross Profit
Operating Expenses $28.49M $20.64M
YoY Change 38.02% 91.38%
Operating Profit $22.64M
YoY Change
Interest Expense $1.328M $600.0K
YoY Change 121.33% 5354.55%
% of Operating Profit 5.87%
Other Income/Expense, Net $1.338M $600.0K
YoY Change 123.0% 34.23%
Pretax Income $23.98M -$12.53M
YoY Change -291.36% 1851.71%
Income Tax $3.690M $4.103M
% Of Pretax Income 15.39%
Net Earnings $20.29M -$8.426M
YoY Change -340.78% 683.09%
Net Earnings / Revenue 35.43% -112.18%
Basic Earnings Per Share $1.05 -$0.44
Diluted Earnings Per Share $0.97 -$0.44
COMMON SHARES
Basic Shares Outstanding 19.30M 19.08M
Diluted Shares Outstanding 21.02M

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $273.2M $192.0M
YoY Change 42.29% -12.13%
Cash & Equivalents $43.09M $22.26M
Short-Term Investments $230.8M $169.8M
Other Short-Term Assets $9.400M $6.600M
YoY Change 42.42% -29.03%
Inventory
Prepaid Expenses
Receivables $57.30M $7.500M
Other Receivables $0.00 $0.00
Total Short-Term Assets $339.9M $206.1M
YoY Change 64.92% -14.76%
LONG-TERM ASSETS
Property, Plant & Equipment $8.400M $8.100M
YoY Change 3.7% 8.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $22.30M $43.30M
YoY Change -48.5% 65.27%
Other Assets $8.500M $18.30M
YoY Change -53.55% 181.54%
Total Long-Term Assets $39.20M $69.70M
YoY Change -43.76% 73.62%
TOTAL ASSETS
Total Short-Term Assets $339.9M $206.1M
Total Long-Term Assets $39.20M $69.70M
Total Assets $379.1M $275.8M
YoY Change 37.45% -2.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.900M $5.500M
YoY Change -10.91% 169.08%
Accrued Expenses $9.100M $5.600M
YoY Change 62.5% 22.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change 0.0%
Total Short-Term Liabilities $14.00M $11.10M
YoY Change 26.13% 16.0%
LONG-TERM LIABILITIES
Long-Term Debt $1.800M $600.0K
YoY Change 200.0% 0.0%
Other Long-Term Liabilities $2.300M $3.300M
YoY Change -30.3% 68.11%
Total Long-Term Liabilities $4.100M $3.900M
YoY Change 5.13% 98.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.00M $11.10M
Total Long-Term Liabilities $4.100M $3.900M
Total Liabilities $18.20M $15.00M
YoY Change 21.33% 16.04%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $360.9M $260.9M
YoY Change
Total Liabilities & Shareholders Equity $379.1M $275.8M
YoY Change 37.45% -2.18%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income $20.29M -$8.426M
YoY Change -340.78% 683.09%
Depreciation, Depletion And Amortization $660.0K $550.0K
YoY Change 20.0% 25.0%
Cash From Operating Activities $4.050M -$4.790M
YoY Change -184.55% 127.01%
INVESTING ACTIVITIES
Capital Expenditures -$1.100M -$740.0K
YoY Change 48.65% 21.31%
Acquisitions
YoY Change
Other Investing Activities -$30.37M $8.400M
YoY Change -461.55% -127.26%
Cash From Investing Activities -$31.46M $7.660M
YoY Change -510.7% -124.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.970M 190.0K
YoY Change 1463.16% -90.31%
NET CHANGE
Cash From Operating Activities 4.050M -4.790M
Cash From Investing Activities -31.46M 7.660M
Cash From Financing Activities 2.970M 190.0K
Net Change In Cash -24.44M 3.060M
YoY Change -898.69% -109.69%
FREE CASH FLOW
Cash From Operating Activities $4.050M -$4.790M
Capital Expenditures -$1.100M -$740.0K
Free Cash Flow $5.150M -$4.050M
YoY Change -227.16% 170.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23978000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3690000
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
34622000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6135000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57262000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7511000
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19303000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20487000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
76000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-9240000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
-3520000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
840000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-564000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
84000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5330000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
22640000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1328000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2017Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-17000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
20288000
us-gaap Profit Loss
ProfitLoss
44536000
us-gaap Profit Loss
ProfitLoss
-18798000
us-gaap Share Based Compensation
ShareBasedCompensation
9861000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1573000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3376000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5686000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22263000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1027000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2584000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2717000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1145000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-12818000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
406000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
879000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4653000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2272000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
186222000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
198823000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27453000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10329000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
266000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
54000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
202000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to,&#160;<font style="Background-color:#FFFFFF;">management&#8217;s judgments of separate units of accounting and best estimate of selling price of those units of accounting within its revenue arrangements; valuation of stock-based awards; and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets.&#160;</font>Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates<font style="color:#000000;">.</font></p></div>
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37821000
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
131696000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
212103000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
773000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
456000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
399000
CY2017Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1175000
CY2017Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
676000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
56.36
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
253843000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
822000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
253022000
CY2017Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
228211000
CY2017 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
9000
CY2017 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
188000
CY2017Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
228032000
CY2018Q2 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
3205000
CY2017Q3 enta Accrued Preclinical And Clinical Expenses Current
AccruedPreclinicalAndClinicalExpensesCurrent
3156000
CY2017Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
1130000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2340000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2829000
CY2017Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
379000
CY2017Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
180000
CY2017Q3 enta Warrants Outstanding And Exercisable
WarrantsOutstandingAndExercisable
1030000
enta Warrants Exercised
WarrantsExercised
978000
enta Warrants Expired
WarrantsExpired
52000
CY2017Q3 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
enta Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
0.01
enta Warrants Expired Weighted Average Exercise Price
WarrantsExpiredWeightedAverageExercisePrice
0.01
CY2018Q2 enta Warrants Weighted Average Exercise Price
WarrantsWeightedAverageExercisePrice
0.01
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2298000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
585000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
194000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
26000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2663000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1551000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.36
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
26.75
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
38.86
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.26
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
31.01
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
33853000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4025000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3102000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11735000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9861000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2018Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1714000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1297000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
117000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1832000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.222
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.329
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1493000
CY2017Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1175000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1519000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1519000
CY2018Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
CY2017Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
608000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
598000

Files In Submission

Name View Source Status
0001564590-18-021062-index-headers.html Edgar Link pending
0001564590-18-021062-index.html Edgar Link pending
0001564590-18-021062.txt Edgar Link pending
0001564590-18-021062-xbrl.zip Edgar Link pending
enta-10q_20180630.htm Edgar Link pending
enta-20180630.xml Edgar Link completed
enta-20180630.xsd Edgar Link pending
enta-20180630_cal.xml Edgar Link unprocessable
enta-20180630_def.xml Edgar Link unprocessable
enta-20180630_lab.xml Edgar Link unprocessable
enta-20180630_pre.xml Edgar Link unprocessable
enta-ex311_8.htm Edgar Link pending
enta-ex312_6.htm Edgar Link pending
enta-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmzggre22yla000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending